Palo Alto Investors Stake in Biomarin Pharmaceutical (BMRN) Raised by $5.28 Million as Stock Price Declined; Institutional Venture Management Xiii Has Decreased Its Care.Com (CRCM) Stake by $28.80 Million; Valuation Declined

April 22, 2018 - By Migdalia James

Care.com, Inc. (NYSE:CRCM) Logo

Institutional Venture Management Xiii Llc decreased its stake in Care.Com Inc. (CRCM) by 64.2% based on its latest 2017Q4 regulatory filing with the SEC. Institutional Venture Management Xiii Llc sold 1.60M shares as the company’s stock declined 9.88% with the market. The institutional investor held 892,080 shares of the consumer services company at the end of 2017Q4, valued at $16.09 million, down from 2.49 million at the end of the previous reported quarter. Institutional Venture Management Xiii Llc who had been investing in Care.Com Inc. for a number of months, seems to be less bullish one the $499.73M market cap company. The stock decreased 0.49% or $0.08 during the last trading session, reaching $16.24. About 81,430 shares traded. Care.com, Inc. (NYSE:CRCM) has risen 41.48% since April 22, 2017 and is uptrending. It has outperformed by 29.93% the S&P500.

William Leland Edwards increased its stake in Biomarin Pharmaceutical Inc (BMRN) by 2.43% based on its latest 2017Q4 regulatory filing with the SEC. Palo Alto Investors Llc bought 59,287 shares as the company’s stock declined 13.73% with the market. The hedge fund run by William Leland Edwards held 2.50 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $222.73M, up from 2.44 million at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be bullish on the $14.49 billion market cap company. The stock decreased 1.58% or $1.32 during the last trading session, reaching $82.3. About 2.28M shares traded or 65.58% up from the average. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since April 22, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

Palo Alto Investors Llc, which manages about $1.30 billion and $2.32B US Long portfolio, decreased its stake in Aimmune Therapeutics Inc by 147,345 shares to 1.15 million shares, valued at $43.36M in 2017Q4, according to the filing. It also reduced its holding in Align Technology Inc (NASDAQ:ALGN) by 10,600 shares in the quarter, leaving it with 212,507 shares, and cut its stake in United Therapeutics Corp Del (NASDAQ:UTHR).

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.08, from 1.13 in 2017Q3. It increased, as 37 investors sold BMRN shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported. Qs Investors Limited Liability Corp reported 7,266 shares stake. Moody Bank & Trust Tru Division invested in 0.01% or 3,290 shares. Parametric Port Assocs Ltd Limited Liability Company accumulated 0.02% or 206,514 shares. Ing Groep Nv reported 4,722 shares. Stone Ridge Asset Mgmt Ltd Limited Liability Company holds 30,700 shares. Hudson Bay Ltd Partnership holds 110,000 shares. Ardsley Advisory Prtn stated it has 0.11% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Keybank Natl Association Oh reported 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Pdts Prtnrs Ltd Liability Com reported 0.95% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Moreover, Ameritas Invest has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 3,126 shares. Virtu Financial Ltd Limited Liability Company holds 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 3,019 shares. Qvt Limited Partnership holds 15,923 shares or 0.08% of its portfolio. Cibc Ww Mkts owns 13,034 shares. Kayne Anderson Rudnick Mngmt Ltd Co holds 0.15% or 204,976 shares. Pictet Asset Management Limited holds 1.31M shares or 0.3% of its portfolio.

Since December 14, 2017, it had 0 insider purchases, and 17 selling transactions for $11.51 million activity. Ajer Jeffrey Robert sold 1,537 shares worth $122,484. 3,750 shares were sold by LAWLIS V BRYAN, worth $333,150 on Tuesday, January 2. 10,000 shares were sold by BIENAIME JEAN JACQUES, worth $846,285. Another trade for 800 shares valued at $71,116 was made by HERON ELAINE J on Thursday, December 14. 10,000 shares valued at $801,200 were sold by FUCHS HENRY J on Monday, April 2.

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical had 87 analyst reports since August 5, 2015 according to SRatingsIntel. Leerink Swann maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Friday, February 23. Leerink Swann has “Outperform” rating and $132 target. The firm earned “Perform” rating on Wednesday, November 18 by Oppenheimer. Cowen & Co maintained the shares of BMRN in report on Thursday, August 3 with “Buy” rating. BMO Capital Markets maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Friday, July 21. BMO Capital Markets has “Buy” rating and $11700 target. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Thursday, July 13 by Deutsche Bank. Piper Jaffray maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Friday, August 5. Piper Jaffray has “Overweight” rating and $120 target. The stock has “Outperform” rating by Credit Suisse on Wednesday, January 20. The rating was maintained by Wedbush with “Hold” on Monday, August 7. On Friday, October 27 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Tuesday, October 3, the company rating was maintained by Robert W. Baird.

Investors sentiment increased to 3.74 in Q4 2017. Its up 2.19, from 1.55 in 2017Q3. It improved, as 10 investors sold CRCM shares while 17 reduced holdings. 46 funds opened positions while 55 raised stakes. 38.36 million shares or 94.63% more from 19.71 million shares in 2017Q3 were reported. Oberweis Asset Management Inc stated it has 1.14% of its portfolio in Care.com, Inc. (NYSE:CRCM). Moreover, Bridgeway Cap Mgmt has 0.02% invested in Care.com, Inc. (NYSE:CRCM). Jacobs Levy Equity Management holds 0.05% or 150,898 shares in its portfolio. Howland Cap Mngmt Lc stated it has 0.04% in Care.com, Inc. (NYSE:CRCM). Ameritas Investment Partners owns 1,247 shares. Us Commercial Bank De reported 0% in Care.com, Inc. (NYSE:CRCM). Strs Ohio invested 0.01% of its portfolio in Care.com, Inc. (NYSE:CRCM). 18,382 are owned by Susquehanna Gp Ltd Liability Partnership. Invesco reported 180,443 shares or 0% of all its holdings. Arrowstreet Capital LP reported 187,177 shares. Legal General Group Pcl, United Kingdom-based fund reported 2,280 shares. Institutional Venture Management Xiii Limited Liability Company holds 12.74% of its portfolio in Care.com, Inc. (NYSE:CRCM) for 892,080 shares. 154,108 are held by Geode Capital Mgmt Llc. Indexiq Advisors Ltd Liability has 0.07% invested in Care.com, Inc. (NYSE:CRCM) for 112,619 shares. Sei holds 485 shares or 0% of its portfolio.

Since November 20, 2017, it had 0 buys, and 24 insider sales for $4.18 million activity. 18,604 Care.com, Inc. (NYSE:CRCM) shares with value of $328,615 were sold by Musi Diane. Echenberg Michael also sold $25,518 worth of Care.com, Inc. (NYSE:CRCM) shares. $299,526 worth of Care.com, Inc. (NYSE:CRCM) was sold by Marcelo Sheila Lirio. Miller J Sanford had sold 31,987 shares worth $558,167.

Analysts await Care.com, Inc. (NYSE:CRCM) to report earnings on May, 2. They expect $0.06 EPS, up 200.00% or $0.04 from last year’s $0.02 per share. CRCM’s profit will be $1.85 million for 67.67 P/E if the $0.06 EPS becomes a reality. After $0.11 actual EPS reported by Care.com, Inc. for the previous quarter, Wall Street now forecasts -45.45% negative EPS growth.

Among 7 analysts covering Care.com (NYSE:CRCM), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Care.com had 17 analyst reports since November 18, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital with “Hold” on Monday, June 12. The firm earned “Hold” rating on Monday, October 23 by Roth Capital. The stock has “Buy” rating by Needham on Friday, November 3. On Friday, September 9 the stock rating was initiated by Roth Capital with “Neutral”. The firm has “Hold” rating given on Wednesday, February 28 by Stifel Nicolaus. On Wednesday, November 18 the stock rating was initiated by Topeka Capital Markets with “Hold”. The stock has “Buy” rating by Roth Capital on Thursday, November 2. As per Thursday, February 4, the company rating was initiated by Morgan Stanley. The stock of Care.com, Inc. (NYSE:CRCM) earned “Buy” rating by Loop Capital on Friday, August 5. Roth Capital maintained it with “Hold” rating and $1400 target in Thursday, August 10 report.

Care.com, Inc. (NYSE:CRCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts